September 8, 2008
Nomir Medical to Present Positive In Vivo Data on MRSA Resistance Reversal in the Human Nares for Its Noveon(R) Dual-Wavelength Device
Nomir Medical Technologies, a leader in the development of optical energy technologies for anti-infective medical applications, announced today that the Company will present an abstract detailing positive in vivo human data from its study of Methicillin-resistant S. aureus (MRSA) resistance reversal and eradication in the nares (nose) using Noveon(R), a novel dual-wavelength optical energy device. Noveon is designed to effect near-infrared photo-damage and photo-inactivation of bacteria and fungi at energies and temperatures that are safe to normal and healthy tissue.
The detailed data will be presented at the Termis North America Annual Conference and Exhibition in San Diego, December 7-10, 2008.
Nomir has completed two IRB-approved human studies with Noveon against MRSA carriage and infection in the human nares. Based on data from these studies, Nomir plans to initiate a proof-of-concept study for Noveon for the reduction of bioburden in diabetic foot ulcers. Additionally, in May 2008, the Company initiated a pivotal product registration trial for Noveon for the treatment of onychomycosis.
Nomir Medical Technologies, Inc. is a medical device company with a product pipeline of optical energy therapeutics being developed for multiple clinical applications. Nomir's light-based systems target the elimination of bacterial and fungal infections, while also promoting healthy tissue recovery. This potential therapy-altering technology may enhance the effectiveness of, or even reduce the need for antibiotics and antifungal agents, and may be associated with fewer treatment side-effects. Nomir has a broad patent portfolio with pending systems, methods and unique photobiological mechanism claims for near infrared photodamage to bacterial and fungal pathogens. www.nomirmedical.com
Certain statements contained in this press release containing words like believe, intend, may, expect, project and other similar expressions are forward-looking statements involving a number of risks and uncertainties. Factors that can cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies, therapies, and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapidly changing technologies; government regulations of our technologies; our ability to assert and enforce our intellectual property rights and protect our proprietary technologies; the ability to attract and retain key employees; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key milestones in key products and other risks factors from time to time in the Company's announcements.